# A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

> **NCT03657810** · PHASE3 · COMPLETED · sponsor: **Charleston Laboratories, Inc** · enrollment: 349 (actual)

## Conditions studied

- Pain
- Nausea
- Vomiting

## Interventions

- **DRUG:** CL-108 5 mg
- **DRUG:** Norco
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03657810
- **Lead sponsor:** Charleston Laboratories, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-02
- **Primary completion:** 2018-04-16
- **Final completion:** 2018-11-30
- **Target enrollment:** 349 (ACTUAL)
- **Last updated:** 2023-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03657810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03657810, "A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03657810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*